Ginkgo Bioworks Receives NYSE Non-Compliance Notice

TL;DR

NYSE flagged $DNA for falling below $1 share price, needs to fix it or risk delisting.

AI Summary

Ginkgo Bioworks Holdings, Inc. announced on September 3, 2024, that it received a notice from the New York Stock Exchange (NYSE) regarding its non-compliance with continued listing standards. The company's common stock has traded below the $1.00 minimum average closing price for 30 consecutive trading days. Ginkgo Bioworks plans to regain compliance by the required deadline.

Why It Matters

This notice indicates potential delisting from the NYSE if compliance is not regained, which could negatively impact the company's stock liquidity and investor confidence.

Risk Assessment

Risk Level: medium — The company is at risk of delisting if it cannot meet the NYSE's minimum share price requirement, which could affect its market standing and investor access.

Key Numbers

• $1.00 — Minimum Share Price (The NYSE requires common stock to maintain an average closing price of at least $1.00 to remain listed.)
• 30 — Consecutive Trading Days (The company's stock has traded below the $1.00 minimum for this duration, triggering the non-compliance notice.)

Key Players & Entities

• Ginkgo Bioworks Holdings, Inc. (company) — Registrant
• New York Stock Exchange (company) — Listing Exchange
• $1.00 (dollar_amount) — Minimum average closing price requirement
• September 3, 2024 (date) — Date of notice

FAQ

Key Financial Figures

• $0.0001 — stered Class A common stock, par value $0.0001 per share DNA NYSE Warrants to purchas
• $11.50 — mon stock, each at an exercise price of $11.50 per share DNA.WS NYSE Indicate by che
• $1.00 — ding on August 30, 2024 were both above $1.00. SIGNATURES Pursuant to the requirem

Filing Documents

• dna-20240903.htm (8-K) — 25KB
• 0001628280-24-039341.txt ( ) — 192KB
• dna-20240903.xsd (EX-101.SCH) — 2KB
• dna-20240903_def.xml (EX-101.DEF) — 16KB
• dna-20240903_lab.xml (EX-101.LAB) — 29KB
• dna-20240903_pre.xml (EX-101.PRE) — 17KB
• dna-20240903_htm.xml (XML) — 4KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. On September 3, 2024, the New York Stock Exchange (the "NYSE") notified Ginkgo Bioworks Holdings, Inc. (the "Company"), and, on September 4, 2024, publicly announced, that the NYSE has determined to (a) commence proceedings to delist the Company's public warrants which were previously issued in connection with Soaring Eagle Acquisition Corp.'s initial public offering (the "Warrants"), each Warrant exercisable for one-fortieth (1/40) of one share of the Company's Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), at an exercise price of $11.50 per Warrant, and listed to trade on the NYSE under the symbol "DNA.WS" and (b) immediately suspend trading in the Warrants due to "abnormally low" trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. Trading in the Company's Class A Common Stock will be unaffected and will continue on the NYSE under the symbol "DNA".

01. Other Events

Item 8.01. Other Events. On September 3, 2024, the Company received a notice from NYSE that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE's noncompliant issuers list. As reported on the Company's Current Report on Form 8-K filed May 13, 2024, the Company had previously received a notice from the NYSE that it was not in compliance with the continued listing minimum price criteria. As of August 30, 2024, the closing price of the Class A Common Stock on August 30, 2024 and the average closing price of the Class A Common Stock over the 30 trading-day period ending on August 30, 2024 were both above $1.00.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GINKGO BIOWORKS HOLDINGS, INC. Date: September 4, 2024 By: /s/ Mark Dmytruk Name: Mark Dmytruk Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR